Nomura Asset Management Co. Ltd. Purchases 10,462 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Nomura Asset Management Co. Ltd. raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.7% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 292,666 shares of the medical research company's stock after buying an additional 10,462 shares during the quarter. Thermo Fisher Scientific makes up about 0.6% of Nomura Asset Management Co. Ltd.'s investment portfolio, making the stock its 29th largest holding. Nomura Asset Management Co. Ltd. owned about 0.08% of Thermo Fisher Scientific worth $181,034,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of TMO. Nisa Investment Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 6.2% during the third quarter. Nisa Investment Advisors LLC now owns 140,708 shares of the medical research company's stock valued at $87,093,000 after purchasing an additional 8,180 shares during the period. Summit Trail Advisors LLC grew its position in Thermo Fisher Scientific by 29.2% in the 3rd quarter. Summit Trail Advisors LLC now owns 5,378 shares of the medical research company's stock valued at $3,329,000 after buying an additional 1,214 shares in the last quarter. Simplify Asset Management Inc. raised its position in shares of Thermo Fisher Scientific by 67.4% during the 3rd quarter. Simplify Asset Management Inc. now owns 13,770 shares of the medical research company's stock worth $8,518,000 after buying an additional 5,546 shares in the last quarter. Simmons Bank lifted its stake in shares of Thermo Fisher Scientific by 60.2% in the 3rd quarter. Simmons Bank now owns 8,224 shares of the medical research company's stock worth $5,087,000 after acquiring an additional 3,090 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Thermo Fisher Scientific by 0.9% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,163,487 shares of the medical research company's stock valued at $1,338,268,000 after acquiring an additional 19,536 shares during the period. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Up 1.5 %

TMO traded up $8.08 on Monday, reaching $537.44. 2,106,629 shares of the company traded hands, compared to its average volume of 1,534,607. Thermo Fisher Scientific Inc. has a 52-week low of $491.33 and a 52-week high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The company has a market cap of $205.57 billion, a price-to-earnings ratio of 33.70, a PEG ratio of 3.56 and a beta of 0.77. The stock's 50 day moving average price is $556.46 and its 200-day moving average price is $575.08.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.03. The business had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. Thermo Fisher Scientific's quarterly revenue was up .2% compared to the same quarter last year. During the same period last year, the company earned $5.69 earnings per share. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.29%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.78%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the sale, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. This represents a 1.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the transaction, the chief executive officer now directly owns 111,192 shares in the company, valued at approximately $58,960,669.92. This represents a 8.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,150 shares of company stock worth $25,954,465 over the last 90 days. Insiders own 0.34% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on TMO shares. TD Cowen upped their target price on Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. UBS Group raised Thermo Fisher Scientific to a "strong-buy" rating in a research note on Monday, September 16th. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating for the company in a report on Thursday, October 24th. Bernstein Bank boosted their target price on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a "market perform" rating in a report on Tuesday, October 22nd. Finally, Redburn Atlantic assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, October 14th. They set a "buy" rating and a $680.00 target price for the company. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $649.33.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.